CARDIOBLATE CRYOFLEX SURGICAL ABLATION SYSTEM

K123733 · Medtronic, Inc. · OCL · Apr 1, 2013 · General, Plastic Surgery

Device Facts

• Record ID: K123733
• Device Name: CARDIOBLATE CRYOFLEX SURGICAL ABLATION SYSTEM
• Applicant: Medtronic, Inc.
• Product Code: OCL · General, Plastic Surgery
• Decision Date: Apr 1, 2013
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4400
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Cardioblate CryoFlex Surgical Ablation System is intended for minimally invasive cardiac surgical procedures, including the treatment of cardiac arrhythmias. The Cardioblate CryoFlex 7 cm, 10 cm, and 10-S probes plus the Clamp and Surgical Ablation Console freeze target tissue and block the electrical conduction pathways by creating an inflammatory response and cryonecrosis.

Device Story

Cryosurgical system for cardiac arrhythmia treatment; utilizes argon-based cryogen for controlled tissue freezing. System components: console, single-use disposable cryoprobes (7cm, 10cm, 10-S, clamp), tank regulator, and accessories. Probes feature integrated thermocouples for temperature monitoring at ablation segment; heat-treated stainless steel shaft with malleable ablation segment; bellows configuration for kink resistance; movable insulative sleeve to adjust ablation zone size. Operated by surgeons in operating room; probe connected to console via hose. Device creates inflammatory response and cryonecrosis to block electrical conduction pathways in cardiac tissue. Benefits include fast, controlled freezing for surgical ablation.

Clinical Evidence

Bench testing only. No clinical data provided.

Technological Characteristics

Argon-based cryosurgical system. Probes constructed of heat-treated stainless steel. Features integrated thermocouple for temperature monitoring. Includes bellows configuration for thermal performance and kink resistance. Malleable shaft design. Single-use, sterile, non-reusable. System includes console, tank regulator, and pressure transducer cable.

Indications for Use

Indicated for patients undergoing minimally invasive cardiac surgical procedures requiring treatment of cardiac arrhythmias. No specific age or gender contraindications provided.

Regulatory Classification

Identification

An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.

Predicate Devices

• Cardioblate® CryoFlex® Surgical Ablation System (K121878)

Submission Summary (Full Text)

{0}------------------------------------------------

K123733 1/3

# 510(k) Summary

## APR 0 1 2013

#### General Information l.

#### Submitter Information a.

| Submitter's Name and<br>Address | Medtronic, Inc.<br>Medtronic Cardiovascular<br>8200 Coral Sea Street NE, MVS83<br>Mounds View, MN 55112 |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person | Kari Christianson<br>Senior Regulatory Affairs Specialist<br>Tel: [phone]<br>FAX: [phone]<br>Email: [e-mail] |

Date of Summary

December 04, 2012

Cryosurgical System

Proprietary Name of Device

Cardioblate CryoFlex Surgical Ablation System

Surgical Device, for Ablation of Cardiac Tissue

Common/Usual Name

Classification Name

Class II, per 21 CFR 878.4350

OCL .

Product Code:

Classification

Predicate Device

Cardioblate® CryoFlex® Surgical Ablation System (K121878)

{1}------------------------------------------------

#### II. Device Description

#### System and Components a.

The Medtronic Cardioblate® CryoFlex® Surgical Ablation Probes, Console, and accessories are used together as a system. The system is composed of the following components:

| Components | Model number |
|--------------------------------------------|--------------|
| Cardioblate CryoFlex Console | 65CS1 |
| Cardioblate CryoFlex Console, Refurbished | R65CS1 |
| Cardioblate CryoFlex 7cm Probe | 60SF7 |
| Cardioblate CryoFlex 10cm Probe | 60SF2 |
| Cardioblate CryoFlex 10S Probe | 60SF3 |
| Cardioblate CryoFlex Clamp with 10cm Probe | 60CM1 |
| Tank Carrier | 65TC1 |
| Tank Regulator | 67RAXNA |
| Tank Regulator, Refurbished | R67RAXNA |
| Pressure Transducer Cable, 6ft. (1.8m) | 67PS6 |
| Gas Hose, 8ft (2.4m) | 67H08 |
| Power Cord, North American | 671PCNA |

### b. System Overview

The Medtronic Cardioblate CryoFlex Surgical Ablation System is a cryoablative surgical device that is used in the cryosurgical treatment of cardiac arrhythmias. The system utilizes an argon-based cryogen for fast, controlled freezing.

The Cardioblate CryoFlex probes are single use, disposable cryoprobes that are designed for use with the system. Each probe has an integrated thermocouple for monitoring temperature at is ablation segment. The probes are supplied sterile, cannot be reused or re-sterilized, and are available in 7cm, 10cm, 10-S (slightly stiffer), and clamp with 10cm probe versions.

The probes shaft and ablation segment are made of specially heat-treated stainless steel. The shaft was designed with enough malleability that the surgeon can easily shape it while still maintaining enough stiffness to ensure its stability in the operating field.

The maileable ablation segment has a bellows configuration, which provides kink resistance and thermal performance. A movable insulative sleeve on the shaft allows the surgeon to vary the size of the ablation zone.

{2}------------------------------------------------

The probe has a 3m (10ft) connection hose which is to be handed out of the sterile field to an operating room nurse for connection to the control panel. Note that once the probe is connected to the control panel, it should not be disconnected until the end of the procedure because it cannot be reconnected. The probe is disabled once it is disconnected.

#### Indications for Use III.

The Cardioblate CryoFlex Surgical Ablation System is intended for minimally invasive cardiac surgical procedures, including the treatment of cardiac arrhythmias. The Cardioblate CryoFlex 7 cm, 10 cm, and 10-S probes plus the Clamp and Surgical Ablation Console freeze target tissue and block the electrical conduction pathways by creating an inflammatory response and cryonecrosis.

There is no change to the indications for use as compared to the predicate device.

#### Comparison to Predicate Devices IV.

The Medtronic Cardioblate CryoFlex Surgical Ablation system is substantially equivalent to the predicate surgical ablation system, has the same intended use and the same design with the exception of the addition of an alternate insulative sheath component on the 7cm, 10cm and 10S probes (Models 60SF7, 60SF2, and 60SF3, respectively) and on the clamp with 10cm probe (Model 60CM1).

#### Summary of Performance Data V.

Verification and validation testing has demonstrated that the Medtronic Cardioblate CryoFlex Surgical Ablation System is substantially equivalent to the predicates.

#### VI. Conclusion

Based on the accumulated technical information, intended use, verification tests and performance data provided, the Cardioblate CryoFlex Surgical Ablation system is substantially equivalent to the currently marketed predicate devices.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or feathers. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol. The logo is printed in black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

## April 1, 2013

Medtronic Inc. c/o Ms. Kari Christianson Senior Regulatory Affairs Specialist 8200 Coral Sea Street NE, Mail Stop MVS83 Mounds View, MN 55112

Re: K123733

Trade/Device Name: Cardioblate CryoFlex Surgical Ablation System Regulation Number: 21 CFR 870.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories. Regulatory Class: II Product Code: OCL Dated: February 6, 2013 Received: February 8, 2013

Dear Ms. Christianson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{4}------------------------------------------------

Page 2 – Ms. Kari Christianson

Please be advised that FDA's issuance of a substantial equivalence determination does not mean . that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820): and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

# Bram D厚ùlokerman

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

## Indications for Use

510(k) Number (if known):

Device Name: Cardioblate CryoFlex Surgical Ablation System

Indications For Use: The Cardioblate CryoFlex Surgical Ablation System is intended for minimally invasive cardiac surgical procedures, including the treatment of cardiac arrhythmias. The Cardioblate CryoFlex 7 cm, 10 cm, and 10-S probes plus CryoFlex Clamp and Surgical Ablation Console freeze target tissue and block the electrical conduction pathways by creating an inflammatory response and cryonecrosis.

Prescription Use X

AND/OR

Over-The-Counter Use

(Part 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Bram D. Zuckerman
2013.04.01 15:17:16
-04'00'

Page 1 of